ABVX

Price Data

Abivax SA is a clinical-stage biotechnology company committed to developing cutting-edge immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is currently undergoing clinical trials for indications such as ulcerative colitis, leveraging a distinctive strategy that combines antibody-mediated therapies with innovative proprietary compounds. With a strong pipeline and a dedicated team of experienced scientists, Abivax aims to address significant unmet medical needs, positioning itself as a compelling investment choice for institutional investors looking to capitalize on emerging opportunities in the immunotherapy sector.